Evidence map›Paper›PMID 27015953›Full record

ArticleArchives of toxicology2017

Fingerprinting of neurotoxic compounds using a mouse embryonic stem cell dual luminescence reporter assay.

Marilena Colaianna, Sten Ilmjärv, Hedi Peterson, Ilse Kern, Stephanie Julien, Mathurin Baquié, Giorgia Pallocca, Sieto Bosgra, Agapios Sachinidis, Jan G Hengstler and 2 more

Abstract readValidation Study
In one paragraph

Article in Archives of toxicology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Stem cell-based test methods.EXCLI journal · 2019
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marilena ColaiannaDepartment of Pathology and Immunology, Medical School, University of Geneva, Geneva, Switzerland.
Sten IlmjärvDepartment of Pathology and Immunology, Medical School, University of Geneva, Geneva, Switzerland.
Hedi PetersonQuretec Ltd, Ülikooli 6a, Tartu, Estonia.
Ilse KernDepartment of Pediatrics, Geneva University Hospital, Geneva, Switzerland.
Stephanie JulienDepartment of Pathology and Immunology, Medical School, University of Geneva, Geneva, Switzerland.
Mathurin BaquiéNEURIX SA, Geneva, Switzerland.
Giorgia PalloccaDoerenkamp-Zbinden Chair for In Vitro Toxicology and Biomedicine, University of Konstanz, Constance, Germany.
Sieto BosgraTNO, Zeist, The Netherlands.
Agapios SachinidisInstitute of Neurophysiology and Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
Jan G HengstlerLeibniz Research Centre for Working Environment and Human Factors (IfADo), Technical University of Dortmund, Dortmund, Germany.
Marcel LeistDoerenkamp-Zbinden Chair for In Vitro Toxicology and Biomedicine, University of Konstanz, Constance, Germany.
Karl-Heinz KrauseDepartment of Pathology and Immunology, Medical School, University of Geneva, Geneva, Switzerland. Karl-Heinz.Krause@unige.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identification of neurotoxic drugs and environmental chemicals is an important challenge. However, only few tools to address this topic are available. The aim of this study was to develop a neurotoxicity/developmental neurotoxicity (DNT) test system, using the pluripotent mouse embryonic stem cell line CGR8 (ESCs). The test system uses ESCs at two differentiation stages: undifferentiated ESCs and ESC-derived neurons. Under each condition, concentration-response curves were obtained for three parameters: activity of the tubulin alpha 1 promoter (typically activated in early neurons), activity of the elongation factor 1 alpha promoter (active in all cells), and total DNA content (proportional to the number of surviving cells). We tested 37 compounds from the ESNATS test battery, which includes polypeptide hormones, environmental pollutants (including methylmercury), and clinically used drugs (including valproic acid and tyrosine kinase inhibitors). Different classes of compounds showed distinct concentration-response profiles. Plotting of the lowest observed adverse effect concentrations (LOAEL) of the neuronal promoter activity against the general promoter activity or against cytotoxicity, allowed the differentiation between neurotoxic/DNT substances and non-neurotoxic controls. Reporter activity responses in neurons were more susceptible to neurotoxic compounds than the reporter activities in ESCs from which they were derived. To relate the effective/toxic concentrations found in our study to relevant in vivo concentrations, we used a reverse pharmacokinetic modeling approach for three exemplary compounds (teriflunomide, geldanamycin, abiraterone). The dual luminescence reporter assay described in this study allows high-throughput, and should be particularly useful for the prioritization of the neurotoxic potential of a large number of compounds.

Indexed as

AnimalsBiomarkersCell CommunicationCell DifferentiationCell LineCell SurvivalCoculture TechniquesDrug Evaluation, PreclinicalDrugs, InvestigationalEnvironmental MonitoringEnvironmental PollutantsGenes, ReporterLuminescent ProteinsMiceMouse Embryonic Stem CellsNeuronsBiomarkersDrugs, InvestigationalEnvironmental PollutantsLuminescent ProteinsNeurotoxinsPeptide Elongation Factor 1Tuba1a protein, mouseTubulinIn vitro screeningMouse embryonic stem cellsNeuroactivityNeuronal differentiationNeurotoxicity

Identifiers

PMID27015953
PMCPMC5225183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.